MARKET

ZOM

ZOM

Zomedica Corp
AMEX

Real-time Quotes | Nasdaq Last Sale

0.1730
-0.0025
-1.42%
After Hours: 0.1729 -0.0001 -0.06% 19:58 12/04 EST
OPEN
0.1780
PREV CLOSE
0.1755
HIGH
0.1789
LOW
0.1701
VOLUME
48.37M
TURNOVER
--
52 WEEK HIGH
0.4990
52 WEEK LOW
0.0628
MARKET CAP
97.58M
P/E (TTM)
-2.1384
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Thinking about buying stock in Iterum Therapeutics, Lizhi Inc, AMC Entertainment, Zomedica, or Aurora Cannabis?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ITRM, LIZI, AMC, ZOM, and ACB.
PR Newswire - PRF · 1d ago
Thinking about buying stock in Sundial Growers, Zomedica, Advanced Micro Devices, Jaguar Health, or Onconova Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, ZOM, AMD, JAGX, and ONTX.
PR Newswire - PRF · 3d ago
Auris Medical Holding leads healthcare gainers; Cocrystal Pharma, Apollo Endosurgery among losers
Gainers: Auris Medical Holding (EARS) +213%. Jaguar Health (JAGX) +56%. F-star Therapeutics (FSTX) +34%. Zomedica (ZOM) +24%. Codiak BioSciences (CDAK) +16%.Losers: Minerva Neurosciences (NERV) -23%. Titan Pharmaceuticals (TTNP) -23%. Cocrystal
Seekingalpha · 3d ago
Is Zomedica Corp. (ZOM) A Good Stock To Buy Now?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
Insider Monkey · 6d ago
Thinking about buying stock in Nio, Titan Pharmaceuticals, Zomedica Corp, Gevo Inc, or Transocean?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, TTNP, ZOM, GEVO, and RIG.
PR Newswire - PRF · 11/23 16:45
Is Zomedica Stock a Buy Right Now? This Analyst Says ‘Yes’
It has been a bountiful November for investors of microcap Zomedica (ZOM). Shares have been on an absolute tear and are up by 120% since the start of the month.According to H.C. Wainwright analyst Swayampakula Ramakanth, there could be plenty more upside on the way.Ramakanth reiterated a Buy rating on ZOM shares, although due to recent share dilution, the analyst slashed his price target from $0.5 to $0.3. Nevertheless, there’s still potential for 93% of gains from current levels. (To watch Ramakanth’s track record, click here)So, what’s behind the surge? Namely the anticipated launch of Truforma.Last Friday, the company announced it will launch the point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs on March 30, 2021.Ramakanth has high hopes for the launch, noting: “We believe TRUFORMA has market potential since a POC diagnostic platform could save time for pet owners, while enabling veterinarians to build better relationships with clients by providing timely diagnosis and treatment.”Additionally, the believes the upcoming launch is “the most important catalyst for the stock in the next six months.” The veterinary market is already huge but is continuously expanding, and by 2027 it is estimated it could be worth over $29 billion. The veterinary diagnostics market on its own is expected to reach $4 billion by 2023.For Truforma, Ramakanth estimates revenues could increase from $4 million in 2021 up to $53 million in 2030.Right now, Zomedica’s focus is on the final development of the two initial Truforma diagnostic panels. The company is also readying for the launch, and has begun putting together its commercial team, which consists of a hybrid model incorporating professional service veterinarians, direct sales representatives, distributors, and distributor support representatives.Ramakanth believes the strategy could yield strong results.“We expect the hybrid commercial team of both distributors and direct sales force could generate synergy since distributors could provide initial sales channels through existing relationship, while direct sales could bring more control over the commercial team,” Ramakanth wrote. As far as the company’s balance sheet is concerned, Zomdica saw out 3Q20 with $52 million of cash in the coffers, which Ramakanth believes “is sufficient to fund operations into the foreseeable future.”Overall, Close’s is the only recent analyst review of this company, and it is decidedly positive. (See ZOM stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 11/18 17:38
Thinking about buying stock in Titan Pharmaceuticals, Norwegian Cruise Line, Delta Air Lines, Zomedica, or Sundial Growers?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTNP, NCLH, DAL, ZOM, and SNDL.
PR Newswire - PRF · 11/18 15:40
KNDI, RIOT, IBIO and GDRX among midday movers
Gainers: Phoenix Tree (DNK) +65%.Lexicon Pharmaceuticals (LXRX) +43%.Riot Blockchain (RIOT) +40%.Zomedica Pharmaceuticals (ZOM) +33%.Miragen Therapeutics (MGEN) +28%.AXT (AXTI) +27%.Glory Star New Media Group (GSMG) +26%.Yunhong CTI (CTIB) +23%.Kandi Technologies (KNDI) +22%.Sequential Brands (SQBG)
Seekingalpha · 11/17 17:44
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZOM. Analyze the recent business situations of Zomedica Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZOM stock price target is 0.5000 with a high estimate of 0.5000 and a low estimate of 0.5000.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 14.30M
% Owned: 2.53%
Shares Outstanding: 564.05M
TypeInstitutionsShares
Increased
10
618.54K
New
6
747.38K
Decreased
7
136.68K
Sold Out
15
2.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
Jeffrey Rowe
President/Chief Operating Officer
Stephanie Morley
Chief Executive Officer/Director
Robert Cohen
Chief Financial Officer/Secretary
Ann Cotter
Executive Director/Other
William MacArthur
Other
Andrea Eberle
Other
Angy Guerrant
Other
Bruk Herbst
Other
Angie Moricz
Director
Christopher Wolfenberg
Independent Director
Tom Robitaille
Independent Director
Jane Eagleson
Independent Director
Jeff Rowe
Independent Director
Christopher MacLeod
Independent Director
Johnny Powers
Independent Director
Thomas Robitaille
Independent Director
Rodney Williams
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZOM
Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Zomedica Corp stock information, including AMEX:ZOM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZOM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZOM stock methods without spending real money on the virtual paper trading platform.